Drug Kinetics – Multimedia

In this webinar, SEKISUI XenoTech study director Dr. Steven McGreal will cover study design elements and other considerations like timing and characteristics of drugs with high RBC partitioning. He will discuss impacts on PK calculations and provide examples of how RBC partitioning rates can cause errors downstream if not properly investigated early in drug development.

Being able to accurately predict drug–target interactions (DTIs) and drug–target binding affinity (DTBA) is crucial in early drug development and during drug repurposing endeavors. Here, we look at some recent research developments in this space.

Although cytochrome P450 (CYP)-mediated metabolism continues to be of major importance for a large proportion of small molecule new drug candidates, various methods in recent decades have accelerated the development of drug candidates with significant non CYP-mediated metabolism.

Drugs elicit their desired therapeutic effects by interacting with specific disease-related targets. However, to determine exactly how a drug works inside the body it is important to address key questions. What type of drug is being used? How is it being administered? What are the characteristics of the individual taking the drug?

This webinar will focus on CYP2C induction and will emphasize when to include CYP2C induction in a study, how to design the study to generate meaningful data and meet the regulatory requirements, what endpoints to measure, and how to interpret results.

It is important to identify the enzymes that significantly contribute to the metabolism of a drug candidate and to evaluate the potential of a drug candidate to be a victim or perpetrator. Knowing how a drug candidate is eliminated by the human body is important in understanding the potential for drug-drug interactions.

In the latest installment of ADME 101, one of our hepatocyte experts answers frequently asked questions about plateable hepatocytes, discusses common reasons why hepatocyte plating fails and demonstrates helpful techniques that will improve the performance of your plated hepatocytes in your in vitro assays.

For this installment of Teach Me in 10, we are joined by the renowned Professor Robert Langer – the most cited engineer of all time – who talks to us about materials for drug delivery.

In this short, information-packed ADME 101 video, one of the principal scientists in our program oversight department discusses the main frequently asked questions that we receive about metabolite identification and characterization studies.

As biology presents ever-more challenging targets, those in the drug discovery field are pushing ahead with new tools to design or discover drugs that have optimal kinetics. But how familiar are you with the key terms used by scientists performing kinetics-directed drug design and discovery? Here, we have compiled a list of key definitions for your reference.